Home › Agent Hub › Agent Tools › Part D coverage by drug › Vyzulta
Agent Tools
Vyzulta is a brand of latanoprostene bunod. What agents check before quoting it: how many 2027 Part D plans cover it, on which tier, with what restrictions and copays, by plan type, carrier and state.
In 2027, 4,443 of 5,492 Medicare Part D and Medicare Advantage drug plans (80.9%) list Vyzulta on their formulary, across 171 of 286 formularies. The most common placement is tier 4 (3,983 plans, 89.6% of those covering it). 7 of the covering plans require prior authorization (0.2%), 28 step therapy and 1,284 a quantity limit. Generic latanoprost is on 5,492 of 5,492 plans (100%).
205 covering plans charge a flat copay for a 30-day supply at a preferred retail pharmacy after the deductible — median $40, 66 of them $0; 4,238 charge coinsurance instead — median 27% of the drug's cost. Once a member's out-of-pocket drug spending reaches $2,400 in 2027, covered drugs cost $0 for the rest of the year.
2026: 4,226 of 5,496 plans covered it (76.9%); 2027: 4,443 of 5,492 (80.9%).
Of 4,367 plans offered in both years, 96 added it to the formulary and 31 dropped it.
Among plans covering it both years, 20 moved it to a higher tier and 252 to a lower one; 0 added prior authorization and 0 removed it.
| Tier | Plans |
|---|---|
| Tier 1 | 68 |
| Tier 3 | 392 |
| Tier 4 | 3,983 |
| Plan type | Plans covering | Share | Prior auth |
|---|---|---|---|
| Stand-alone Part D (PDP) | 252 of 323 | 78% | 0% |
| Medicare Advantage with drugs (MA-PD) | 2,495 of 3,200 | 78% | 0.2% |
| Special needs plans (SNP) | 1,696 of 1,969 | 86.1% | <0.1% |
| Carrier | Plans covering | Usual tier | Prior auth |
|---|---|---|---|
| Humana | 846 of 846 | Tier 4 | 0 |
| UnitedHealthcare | 830 of 830 | Tier 4 | 0 |
| Devoted Health | 728 of 728 | Tier 4 | 0 |
| Aetna Medicare | 611 of 631 | Tier 4 | 0 |
| Wellcare | 268 of 268 | Tier 3 | 0 |
| HealthSpring | 0 of 226 | No tier listed | 0 |
| Kaiser Permanente | 0 of 112 | No tier listed | 0 |
| SCAN Health Plan | 83 of 83 | Tier 4 | 0 |
| Highmark Blue Cross Blue Shield or Highmark Blue Shield | 0 of 80 | No tier listed | 0 |
| Alignment Health Plan | 77 of 77 | Tier 3 | 0 |
| Anthem Blue Cross and Blue Shield | 74 of 74 | Tier 4 | 0 |
| Wellpoint | 63 of 63 | Tier 4 | 0 |
| Priority Health Medicare | 0 of 40 | No tier listed | 0 |
| CarePlus Health Plans, Inc. | 37 of 37 | Tier 4 | 0 |
| Zing Health | 36 of 36 | Tier 4 | 0 |
| Capital Blue Cross | 0 of 35 | No tier listed | 0 |
| Prominence Health Plan | 0 of 29 | No tier listed | 0 |
| Medica | 0 of 27 | No tier listed | 0 |
| Anthem HealthKeepers | 26 of 26 | Tier 4 | 0 |
| Blue Cross Blue Shield of Michigan | 26 of 26 | Tier 4 | 0 |
| State | Plans covering | Share |
|---|---|---|
| Alabama | 87 of 114 | 76.3% |
| Alaska | 7 of 9 | 77.8% |
| American Samoa | 1 of 1 | 100% |
| Arizona | 137 of 147 | 93.2% |
| Arkansas | 71 of 85 | 83.5% |
| California | 333 of 397 | 83.9% |
| Colorado | 82 of 106 | 77.4% |
| Connecticut | 53 of 54 | 98.1% |
| Delaware | 35 of 43 | 81.4% |
| District of Columbia | 9 of 12 | 75% |
| Florida | 420 of 545 | 77.1% |
| Georgia | 115 of 149 | 77.2% |
| Guam | 1 of 1 | 100% |
| Hawaii | 43 of 50 | 86% |
| Idaho | 40 of 45 | 88.9% |
| Illinois | 111 of 132 | 84.1% |
| Indiana | 133 of 138 | 96.4% |
| Iowa | 54 of 64 | 84.4% |
| Kansas | 74 of 84 | 88.1% |
| Kentucky | 114 of 121 | 94.2% |
| Louisiana | 109 of 125 | 87.2% |
| Maine | 51 of 52 | 98.1% |
| Maryland | 32 of 49 | 65.3% |
| Massachusetts | 82 of 89 | 92.1% |
| Michigan | 123 of 182 | 67.6% |
| Minnesota | 28 of 63 | 44.4% |
| Mississippi | 90 of 104 | 86.5% |
| Missouri | 151 of 170 | 88.8% |
| Montana | 25 of 27 | 92.6% |
| Nebraska | 43 of 51 | 84.3% |
| Nevada | 83 of 100 | 83% |
| New Hampshire | 24 of 25 | 96% |
| New Jersey | 65 of 73 | 89% |
| New Mexico | 58 of 68 | 85.3% |
| New York | 163 of 215 | 75.8% |
| North Carolina | 150 of 176 | 85.2% |
| North Dakota | 18 of 26 | 69.2% |
| Northern Mariana Islands | 1 of 1 | 100% |
| Ohio | 133 of 171 | 77.8% |
| Oklahoma | 64 of 81 | 79% |
| Oregon | 76 of 92 | 82.6% |
| Pennsylvania | 171 of 323 | 52.9% |
| Puerto Rico | 62 of 64 | 96.9% |
| Rhode Island | 23 of 29 | 79.3% |
| South Carolina | 75 of 89 | 84.3% |
| South Dakota | 20 of 30 | 66.7% |
| Tennessee | 134 of 156 | 85.9% |
| Texas | 339 of 407 | 83.3% |
| U.S. Virgin Islands | 1 of 1 | 100% |
| Utah | 49 of 53 | 92.5% |
| Vermont | 13 of 14 | 92.9% |
| Virginia | 129 of 144 | 89.6% |
| Washington | 85 of 114 | 74.6% |
| West Virginia | 47 of 69 | 68.1% |
| Wisconsin | 74 of 96 | 77.1% |
| Wyoming | 11 of 13 | 84.6% |
Medicare Part D paid for 456,040 30-day fills of Vyzulta in 2024 for about 75,802 enrollees, at an average total cost of $281.24 per 30-day fill (CMS Part D Prescribers by Geography and Drug, national).
Price Vyzulta and the rest of a client's list on every plan in their county.
Estimate Vyzulta costs by plan
Free tools for licensed insurance agents. Data from CMS public files; verify with plan documents before advising a client.
Counts are over every Medicare Advantage drug plan and stand-alone Part D plan in the CMS monthly formulary files, excluding employer plans. A plan counts as covering a drug when any strength or form of it is on the plan’s formulary; the tier, prior authorization, step therapy and quantity limit shown are the most favorable version on that formulary. Copays are for a 30-day supply at a preferred retail pharmacy after the deductible. This is a reference for licensed agents, not a plan recommendation; verify with the plan’s formulary before advising a client. Source: CMS Part D formulary files (release 10/08/2026). CMS formulary data.